A. Patat

发表

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.

J. O'hanlon, J. Ramaekers, J. Louwerens, 1999, Journal of clinical psychopharmacology.

A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

P. Rosenzweig, A. Patat, M. Canal, 2002, Human psychopharmacology.

A study of the pharmacodynamic interaction between befloxatone and ethanol on performance and mood in healthy volunteers

J. O'hanlon, J. Ramaekers, N. Muntjewerff, 1996, Journal of psychopharmacology.

Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects

B. Sexton, A. Irving, A. Patat, 2004, European Journal of Clinical Pharmacology.

Driving, drug research and the pharmaceutical industry

A. Patat, 1998 .

An Evaluation of the Potential of Cytochrome P450 3A4-Mediated Drug-Drug Interactions with Desvenlafaxine Use

J. Posener, A. Patat, J. Paul, 2013 .

Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol.

W. Riedel, M. V. van Boxtel, A. Patat, 2002, Sleep.

Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis

A. Patat, M. Morgan, C. Gleiter, 2011, Journal of clinical pharmacology.

The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double‐Blind, Clinical Trial

A. Patat, A. Kovar, A. Johne, 2012, Clinical pharmacology and therapeutics.

Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study

A. Patat, A. Falcão, P. Soares-da-Silva, 2015, Clinical pharmacology in drug development.

Safety, Pharmacokinetic, and Pharmacodynamic Evaluations of PI‐2301, a Potent Immunomodulator, in a First‐in‐Human, Single‐Ascending‐Dose Study in Healthy Volunteers

A. Patat, N. Fauchoux, E. Zanelli, 2011, Journal of clinical pharmacology.

Pharmacokinetic interactions of OBE001 and betamethasone in healthy female volunteers

A. Patat, O. Pohl, A. Chollet, 2015, Journal of clinical pharmacy and therapeutics.

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

A. Patat, J. Dingemanse, P. V. van Giersbergen, 2010, Antiviral therapy.

Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist

T. Hergueta, A. Puech, A. Patat, 1994, International clinical psychopharmacology.

Use of zolpidem 10 mg as a benzodiazepine substitute in 84 patients with insomnia

A. Patat, J. Gandon, H. Allain, 1998 .

Large-conductance calcium-activated potassium channel haploinsufficiency leads to sensory deficits in the visual system: a case report

A. Patat, R. Ring, S. Briault, 2022, Journal of Medical Case Reports.

Effect of drugs on mnestic performance: a methodological approach

A. Patat, S. Belliard, M. Caldwell, 1996 .

Pharmacokinetics, safety, and tolerability of the 2‐ and 3‐direct‐acting antiviral combination of AL‐335, odalasvir, and simeprevir in healthy subjects

A. Patat, Qingling Zhang, T. Kakuda, 2018, Pharmacology research & perspectives.

Pressor Effect of Oral Tyramine During Treatment with Befloxatone, a New Reversible Monoamine Oxidase‐A Inhibitor, in Healthy Subjects

A. Patat, G. Durrieu, I. Berlin, 1995, Journal of clinical pharmacology.

Emotion, anxiolysis and memory

M. Bourin, A. Patat, H. Allain, 1999 .

Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers.

A. Patat, N. Fauchoux, N. Pross, 2015, British journal of clinical pharmacology.

Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects.

P. Rosenzweig, A. Patat, P. Morselli, 1992, British journal of clinical pharmacology.

Determination of the maximal tolerated dose of a new acute oral caffeine formulation in healthy volunteers

A. Patat, F. Chauffard, M. Enslen, 1996 .

PI‐73

A. Patat, C. Reh, N. Fauchoux, 2006 .

Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS‐233 SR) in healthy subjects

A. Patat, V. Parker, J. Behrle, 2005 .

Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2012, Clinical pharmacology in drug development.

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2013, European Journal of Clinical Pharmacology.

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2013, European Journal of Clinical Pharmacology.

Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Severe Hepatic Impairment

A. Patat, R. Moirand, Kyle T. Matschke, 2008, Journal of clinical pharmacology.

Absolute Bioavailability and Electroencephalographic Effects of Conventional and Extended‐Release Formulations of Venlafaxine in Healthy Subjects

A. Patat, S. Troy, S. Trocherie, 1998, Journal of clinical pharmacology.

Bioequivalence & Bioavailability

J. Posener, A. Patat, J. Paul, 2011 .

Clinical pharmacology of psychotropic drugs

A. Patat, 2000, Human psychopharmacology.

EEG profile of litoxetine after single and repeated administration in healthy volunteers.

P. Rosenzweig, A. Patat, G. Bianchetti, 1994, British journal of clinical pharmacology.

Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects

M. J. Klein, A. Patat, M. Hucher, 2005, Psychopharmacology.

Study of the potential pharmacodynamic antagonism of RU 41 656 on scopolamine and triazolam impairment in healthy subjects

M. J. Klein, A. Patat, M. Hucher, 1990 .

Clinical pharmacology of befloxatone: a brief review.

P. Rosenzweig, A. Patat, G. Durrieu, 1998, Journal of affective disorders.

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.

Dominique Larrey, Stefan Zeuzem, Alain Patat, 2011, Journal of hepatology.

Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects

A. Patat, Qingling Zhang, A. Streinu-Cercel, 2018, PloS one.

Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects.

A. Patat, G. Ferron, S. Troy, 2003, British journal of clinical pharmacology.

Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.

Dominique Larrey, Stefan Zeuzem, Alain Patat, 2011, The Journal of infectious diseases.

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

A. Patat, R. Jenkins, H. Jenkins, 2017, Clinical Drug Investigation.

Electroretinography and contrast sensitivity, complementary translational biomarkers of sensory deficits in the visual system of individuals with fragile X syndrome

A. Patat, R. Ring, S. Raab, 2021, Journal of neurodevelopmental disorders.

Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic

P. Rosenzweig, A. Patat, A. Forster, 1994, Clinical pharmacology and therapeutics.

Designing and interpreting the results of first-time-to-man studies

A. Patat, 2000, Dialogues in clinical neuroscience.

Lack of Amphetamine‐Like Effects After Administration of Mefenorex in Normal Young Subjects

A. Patat, S. Trocherie, J. Gandon, 1996 .

A single-dose PK study of onapristone including the effect of food on absorption

A. Patat, D. Chassard, A. Bexon, 2015, Cancer Chemotherapy and Pharmacology.

A Study of the Potential Interaction Between Bazedoxifene and Atorvastatin in Healthy Postmenopausal Women

A. Patat, J. Ermer, W. McKeand, 2018, Clinical pharmacology in drug development.

Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.

A. Patat, D. Chassard, A. Płotka, 2009, British journal of clinical pharmacology.

Effect on postural sway of various benzodiazepine tranquillizers.

A. Patat, P. Foulhoux, 1985, British journal of clinical pharmacology.

Acute effects of amitriptyline on human performance and interactions with diazepam

M. J. Klein, A. Patat, M. Hucher, 2004, European Journal of Clinical Pharmacology.

Effects of acute and repeated doses of two muscle relaxants chlormezanone and thiocolchicoside, on vigilance and psychomotor performance of healthy volunteers

M. J. Klein, A. Patat, Y. Rezvani, 1991 .

Effects of single oral doses of clobazam, diazepam and lorazepam on performance tasks and memory

M. J. Klein, A. Patat, M. Hucher, 2004, European Journal of Clinical Pharmacology.

Study of effects of clobazam and lorazepam on memory and cognitive functions in healthy subjects

M. J. Klein, A. Patat, A. Surjus, 1991 .

Alpidem: Lack of sedative effect on psychomotor performance in therapeutic doses

P. Rosenzweig, A. Patat, L. Bergougnan, 1993 .

Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers

P. Rosenzweig, A. Patat, I. Zieleniuk, 1995, Journal of psychopharmacology.

Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography.

J. Baron, A. Patat, B. Scatton, 1996, European journal of pharmacology.

[Residual effects on the equilibrium of 3 hypnotics (loprazolam, flunitrazepam, triazolam) assessed by spectrum analysis of postural oscillations].

M. J. Klein, A. Patat, P. Foulhoux, 1986, Therapie.

A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group.

A. Patat, H. Caplain, M. Sibille, 2010, British journal of clinical pharmacology.

SafetyLit is a free service of the Center for Injury Prevention Policy and Practice at San Diego State University in collaboration with the World Health Organization.

A. Patat, H. Allain, Y. Akwa, 2006 .

Pharmacodynamic profile of Zaleplon, a new non‐benzodiazepine hypnotic agent

I. Hindmarch, A. Patat, I. Paty, 2001, Human psychopharmacology.

Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen

A. Patat, J. Ermer, W. McKeand, 2018, Clinical pharmacology in drug development.

Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics

A. Patat, H. Allain, A. Lieury, 1995, European Psychiatry.

Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin

A. Patat, Honghui Zhou, J. Korth-Bradley, 2004, Journal of clinical pharmacology.

Residual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening

Neil Stanley, Alain Patat, I. Hindmarch, 2001, Human psychopharmacology.

EEG profile of intravenous zolpidem in healthy volunteers

P. Rosenzweig, A. Patat, G. Bianchetti, 1994, Psychopharmacology.

Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep‐deprived subjects

Alain Patat, P. Rosenzweig, A. Patat, 2000, Human psychopharmacology.

EEG, MAO‐A inhibition, pharmacokinetics and safety of befloxatone in the elderly

P. Rosenzweig, A. Patat, G. Durrieu, 1997 .

Specifications for building a vertical force platform designed for clinical stabilometry

G. Bizzo, N. Guillet, A. Patat, 1985, Medical and Biological Engineering and Computing.

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites

A. Patat, D. Guyader, E. Ellis-Grosse, 2002, Hepatology.

Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects.

M. Toussaint, R. Luthringer, J. Macher, 1996, Neuropsychobiology.

Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor

P. Rosenzweig, A. Patat, I. Zieleniuk, 1998, Clinical pharmacology and therapeutics.

Residual Effects of Middle-of-the-Night Administration of Zaleplon and Zolpidem on Driving Ability, Memory Functions, and Psychomotor Performance

Joris C Verster, Alain Patat, M. Verbaten, 2002, Journal of clinical psychopharmacology.

Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers

P. Rosenzweig, A. Patat, J. Danion, 1997, Psychopharmacology.

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

A. Patat, F. Pizzagalli, L. Ereshefsky, 2016, Psychopharmacology.

RU 41 656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers

M. J. Klein, A. Patat, M. Hucher, 2004, European Journal of Clinical Pharmacology.

An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.

A. Patat, J. Paul, V. Parker, 2013, Clinical therapeutics.

Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin

A. Patat, D. Simcoe, Honghui Zhou, 2004, Journal of clinical pharmacology.

Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.

P. Rosenzweig, A. Patat, I. Zieleniuk, 1995, British journal of clinical pharmacology.

Effects of single and multiple doses of a new reversible MAO‐A inhibitor, befloxatone, on psychomotor performance and memory in healthy subjects

A. Patat, G. Durrieu, O. Curet, 1995 .

Effects of Befloxatone, a Reversible Selective Monoamine Oxidase‐A Inhibitor, on Psychomotor Function and Memory in Healthy Subjects

A. Patat, G. Durrieu, I. Zieleniuk, 1996, Journal of clinical pharmacology.

Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test.

Joris C Verster, Berend Olivier, Alain Patat, 2006, Current drug safety.

Safety and tolerance of single oral doses of trandolapril (RU 44.570), a new angiotensin converting enzyme inhibitor

A. Patat, A. L. Go, A. Surjus, 2004, European Journal of Clinical Pharmacology.

Effects of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects

P. Rosenzweig, A. Patat, L. Gram, 1994, International clinical psychopharmacology.

Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies

P. Rosenzweig, A. Patat, 1999, Clinical and Experimental Allergy.

Pharmacodynamics and Pharmacokinetics of Two Dose Regimens of Befloxatone, a New Reversible and Selective Monoamine Oxidase Inhibitor, at Steady State in Healthy Volunteers

Olivier Curet, Alain Patat, P. Rosenzweig, 1996, Journal of clinical pharmacology.

SODIUMOXYBATE IN THE PREVENTION OFALCOHOL RELAPSES IN ALCOHOL DEPENDENT PATIENTS (GATE 2 STUDY)

A. Patat, G. Addolorato, J. Horodnicki, 2013 .

Absolute/Relative Bioavailability of Bazedoxifene Acetate in Healthy Postmenopausal Women

A. Patat, J. Ermer, F. Lecoz, 2003, Clinical Pharmacology & Therapeutics.

Lack of Pharmacokinetic Interaction Co‐Administered of Sirolimus and Tacrolimus

A. Patat, J. Zimmerman, V. Parks, 2003 .

Mnestic Performance: Approach

A. Patat, S. Belliard, J. Gandon, 2004 .

The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers.

I. Hindmarch, P. Rosenzweig, A. Patat, 1995, British journal of clinical pharmacology.

Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly : A comparative review

A. Patat, H. Allain, Y. Akwa, 2005 .

Effects of a new slow release formulation of caffeine on EEG, psychomotor and cognitive functions in sleep‐deprived subjects

P. Rosenzweig, A. Patat, M. Enslen, 2000, Human psychopharmacology.

Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep‐deprived subjects

P. Rosenzweig, A. Patat, J. Gandon, 1999, Fundamental & clinical pharmacology.

Dose-response relationship of vindeburnol based on spectral analysis of posturographic recordings

A. Patat, A. L. Go, P. Foulhoux, 2004, European Journal of Clinical Pharmacology.

A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5‐Hydroxytryptamine‐1A Silent Antagonist, to Brain 5‐HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease

B. Långstrom, A. Patat, J. Paul, 2008, Clinical pharmacology and therapeutics.

The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double‐Blind, Clinical Trial

A. Patat, A. Kovar, A. Johne, 2012, Clinical pharmacology and therapeutics.

Driving, drug research and the pharmaceutical industry

A. Patat, 1998 .

EEG, MAO‐A inhibition, pharmacokinetics and safety of befloxatone in the elderly

P. Rosenzweig, A. Patat, G. Durrieu, 1997 .

Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.

A. Patat, B. Stone, S. L. Mills, 2002, British journal of clinical pharmacology.

Comparison of psychomotor and memory impairment with zaleplon versus other hypnotics: an integrated analysis

A. Patat, S. Troy, M. Darwish, 2000, European Neuropsychopharmacology.

Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics

A. Patat, H. Allain, A. Lieury, 1995, European Psychiatry.

Effect of bromazepam versus placebo on inhibition and waiting capacity in young women with traits of anxiety

A. Patat, J. Gandon, H. Allain, 1998, Fundamental & clinical pharmacology.

Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women

A. Patat, J. Ermer, W. McKeand, 2018, Clinical pharmacology in drug development.